AstraZeneca AZN announced positive results from an interim analysis of the ongoing late-stage I CAN study, which evaluated ...

Seven years after the FDA's accelerated approval of bleeding reversal agent Andexxa, which was then under the ownership of Portola Pharmaceuticals, the drug's round trip on the U.S. market is coming ...

AstraZeneca has returned to recent licensing partner CSPC Pharmaceutical with $110 million in upfront cash to start work on finding new oral drugs for a range of chronic diseases. The Friday morning ...

AstraZeneca showcases three new pioneering drugs at major cancer convention in Berlin. AstraZeneca is enjoying a banner year, averaging a successful phase-three readout every month. The chief ...

A phase 3 study of AstraZeneca’s ceralasertib has missed its primary endpoint, dealing another blow to efforts to use a synthetic lethal mechanism to overcome resistance to immuno-oncology drugs. The ...

Nearly a year after earning the first-ever FDA approval for a self-administered flu vaccine, AstraZeneca has kicked off a new service delivering its FluMist directly to consumers. FluMist has been ...

SHANGHAI, Jan 30 (Reuters) - AstraZeneca (AZN.L), opens new tab will license experimental drugs for obesity and weight-related conditions from CSPC Pharmaceutical Group (1093.HK), opens new tab and ...

President Trump on Friday announced another major pharmaceutical company had agreed to his “most favored nation” (MFN) policy, pledging that the cost to Medicaid patients for its drugs remains on par ...

AstraZeneca (AZN) shares added ~2% in the premarket on Tuesday after the Anglo-Swedish drugmaker exceeded Street forecasts with its Q4 2025 financials, thanks mainly to its oncology portfolio. The U.K ...

AstraZeneca’s intranasal, needle-free vaccine FluMist has been around for more than two decades but now it’s available for people to use in the comfort of their own homes. On Friday morning, the ...